This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why
by Zacks Equity Research
Kazia (KZIA) surges after positive data from a phase II/III study on its lead pipeline drug in patients with glioblastoma. Based on this data, it plans to seek an accelerated nod from the FDA.
Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Heron Therapeutics (HRTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
United Therapeutics (UTHR) Completes Enrolment in IPF Study
by Zacks Equity Research
United Therapeutics' (UTHR) late-stage study is evaluating Tyvaso inhalation solution in IPF patients living outside the United States and Canada.
New Strong Buy Stocks for July 11th
by Zacks Equity Research
SKIL, INKT, MLCO, GTLB, and HRTX have been added to the Zacks Rank #1 (Strong Buy) List on July 11, 2024.
Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View
by Zacks Equity Research
Indivior (INDV) slashes financial guidance for 2024, primarily to reflect adverse sales conditions of its top-selling opioid drug. It will discontinue the sales of its schizophrenia drug.
Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner
by Zacks Equity Research
Merck (MRK) exercises the option that will convert the collaboration deal with partner Orion for prostate cancer candidate opevesostat into a license agreement.
FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease
by Zacks Equity Research
Per the FDA, Rocket (RCKT) needs to submit additional manufacturing information on Kresladi gene therapy to secure approval for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.
FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma
by Zacks Equity Research
Following the label expansion, AbbVie's (ABBV) Epkinly is the first bispecific antibody approved to treat relapsed/refractory (R/R) follicular lymphoma and R/R diffuse large B-cell lymphoma.
AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer
by Zacks Equity Research
Data from a late-stage study shows that treatment with AstraZeneca's (AZN) Imfinzi plus chemotherapy before and after bladder removal surgery improves survival in patients.
Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
by Zacks Equity Research
Per argenx (ARGX), the label expansion to Vyvgart Hytrulo makes it the first FDA-approved medication with a novel mechanism of action to treat chronic inflammatory demyelinating polyneuropathy.
OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies
by Zacks Equity Research
Two late-stage studies, which evaluated Ovid Therapeutics' (OVID) experimental drug for two forms of epilepsy, fail to meet their primary endpoints.
Avidity (RNA) Up 33% on Rare Muscle Disease Study Results
by Zacks Equity Research
Initial data from an early-stage study shows that treatment with Avidity's (RNA) experimental therapy could address the underlying cause of a rare muscle-weakening condition.
FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D
by Zacks Equity Research
Following the label expansion, AstraZeneca's (AZN) Farxiga is now approved to improve glycemic control in patients aged 10 years and older with T2D. It was previously approved for such use in adults.
Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why
by Zacks Equity Research
Summit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental antibody beat Merck's Keytruda in a head-to-head setting in treating certain patients with lung cancer.
Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug
by Zacks Equity Research
Viridian (VRDN) intends to initiate two late-stage studies on its experimental thyroid eye disease drug this August. Top-line data from both studies are expected in first-half 2026
Amgen's (AMGN) Uplizna Meets Study Goal for Rare Disease
by Zacks Equity Research
Data from a late-stage study shows that treatment with Amgen's (AMGN) Uplizna achieves a statistically significant reduction in the risk of flares in patients with IgG4-RD, a rare disease.
Eli Lilly (LLY) Veteran Anat Ashkenazi to Join Alphabet as CFO
by Zacks Equity Research
Eli Lilly (LLY) CFO Anat Ashkenazi joins Google's parent company Alphabet as CFO and senior vice president, effective from Jul 31, 2024
Here's Why You Should Consider Buying Bioventus (BVS) Stock
by Zacks Equity Research
Here, we discuss some reasons why buying Bioventus (BVS) stock now may turn out to be a prudent move.
Agios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study
by Zacks Equity Research
Data from a late-stage study shows that transfusion-dependent thalassemia patients who received Agios' (AGIO) Pyrukynd demonstrated a statistically significant reduction in transfusion burden.
Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody
by Zacks Equity Research
Biogen's (BIIB) Qalsody is the first therapy approved to treat a rare genetic form of ALS in Europe
J&J's (JNJ) Oral Pill Improves Depression & Insomnia Symptoms
by Zacks Equity Research
Data from a late-stage study shows that treatment with J&J's (JNJ) experimental drug met all study endpoints in depression patients with insomnia symptoms.
Merck (MRK) to Buy Private Ophthalmology Company EyeBio
by Zacks Equity Research
Merck's (MRK) acquisition of EyeBio is set to add the latter's lead pipeline candidate, Restoret, a novel Wnt agonist antibody being developed for treating retinal diseases.
Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) agrees to sell to Royalty Pharma the rights to royalties on potential net sales of a brain cancer drug that was sold to Servier in 2021.
Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data
by Zacks Equity Research
Data from a late-stage study shows that treatment with Insmed's (INSM) brensocatib reduced episodes of worsening disease symptoms in patients with bronchiectasis, a chronic lung condition.